Autoimmune liver disease.
The incidence and prevalence of autoimmune hepatitis are greater than expected among white northern Europeans. Patients with type 2 autoimmune hepatitis have different HLA frequencies than patients with type 1 disease and HLA-DRB1*07 may be an important risk factor. Hepatitis C virus can trigger autoimmune hepatitis after needlestick inoculation. Elderly patients have milder disease than young patients and they are frequently untreated. Cryptogenic chronic hepatitis is indistinguishable from autoimmune hepatitis and it responds as well to corticosteroids. Variant syndromes are common and the degree of cholestasis influences the treatment response. Endomysial antibodies indicate celiac sprue in asymptomatic patients, and multiple endocrinopathies in individuals with type 2 disease may reflect molecular mimicries and cross-reacting autoantibodies. Phase I (cytochromes P-450) and phase II (uridine diphosphate glucuronosyltransferases) drug-metabolizing enzymes are the autoantigens of syndromes characterized by liver/kidney microsomal autoantibodies. T-cell vaccination prevents the occurrence of experimental hepatitis in mice and it can also treat the disease. Liver transplantation can be complicated by recurrent disease, frequent allograft rejection, and de novo autoimmune hepatitis.